This clinical study is designed to collect data for further development of a hypoglycaemia notification algorithm. In addition, information regarding safety will be collected and analysed.
H02 is an implantable continuous EEG recorder that consists of an implant and an external device. The H02 system is based on a subcutaneous EEG measurement and acquisition of the EEG signal from the implant. Participant will have the implantable part of H02 implanted under local anaesthesia. After a healing period, the participants will start using the external part of H02. They will wear the external part of H02 as much as possible both during daytime and night-time. The participant will use their own continuous glucose monitoring (CGM) during the study as normal practice. The participants will be exposed to insulin-induced hypoglycaemia once during the study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
The H02 device consists of two parts: 1. An implantable part which records the EEG signal and transmits the signal wirelessly to the external device. 2. The external device receiving signals and storing data from the implant.
To collect electrocardiogram (EEG) data to develop a hypoglycaemia notification algorithm.
Recording of EEG characteristic hypoglycaemic related changes and EEG during normoglycemia measured as number of hours EEG data from each participant.
Time frame: 7-8 months
To collect self-measured blood glucose (SMBG) data to develop a hypoglycaemia notification algorithm.
Number SMBG measurements below 3 mmol/L glucose per participant
Time frame: 7-8 months
To collect continuous glucose monitoring (CGM) data to develop a hypoglycaemia notification algorithm.
Number of CGM values below 3 mmol/L glucose per participant
Time frame: 7-8 months
To evaluate the safety of H02 in participants with type 1 diabetes.
* Number of adverse events 29 weeks after implantation (from visit 3 to visit 14) * Number of adverse device effects (ADEs) 29 weeks after implantation (from visit 3 to visit 14)
Time frame: 7-8 months
To evaluate the performance of H02 in participants with type 1 diabetes.
Number of device deficiencies (from visit 3 to visit 13)
Time frame: 7-8 months
To evaluate the surgeon satisfaction of H02 in participants with type 1 diabetes.
Surgeon satisfaction will be evaluated by questionnaires after the implantation at visit 3 and after explantation at visit 13 of the implantable part of Hyposafe H02 Device
Time frame: 0 and 7-8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.